Stocks & Indices Unverified First seen 2026-10-28 14:02 UTC

Eli Lilly says retatrutide beat Ozempic in head-to-head study

Eli Lilly said Wednesday that its next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, according to Investor's Business Daily. The post states the company's claim but gives no figures, timing or independent confirmation.

Why “Unverified”

Reported by Investor's Business Daily alone, with no second source or primary confirmation yet

1 independent source group across 1 post · evidence score 52/100. How labels work

Market around the story

LLY Still being measured. The price reaction is recorded once the market has traded for six hours after the first report.

What the sources claim

Eli Lilly said its next-generation weight-loss drug retatrutide beat Novo's Ozempic in a head-to-head study. LLY

“retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday”
Investor's Business Daily

Sources

Investor's Business Daily newswire 2026-10-28 14:02 UTC
Eli Lilly's Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test

More on LLY

All LLY stories →

Summary and claims extracted by AI with prompt analyze-story@5 on 2026-10-28 14:10 UTC. Labels are computed from the sources, not by the model.